Get the Stockscreener App
11.04
0.99%
-0.11
After Hours:
11.05
0.01
+0.09%
Telix Pharmaceuticals Ltd Adr stock is traded at $11.04, with a volume of 89,211.
It is down -0.99% in the last 24 hours and up +20.92% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$11.15
Open:
$11.15
24h Volume:
89,211
Relative Volume:
0.36
Market Cap:
$3.74B
Revenue:
$804.63M
Net Income/Loss:
$-7.13M
P/E Ratio:
-523.22
EPS:
-0.0211
Net Cash Flow:
$-73.42M
1W Performance:
+5.75%
1M Performance:
+20.92%
6M Performance:
+7.29%
1Y Performance:
-40.61%
1-Day Range:
$10.97
$11.15
1-Week Range:
$10.39
$11.30
52-Week Range:
$6.28
$18.49
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
11.04 | 3.78B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC - GlobeNewswire Inc.
TLX101-Px (Pixlumi®) MAA Accepted in Europe - Sahm
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Strengthens Board with Additional Director Appointments - Sahm
Telix Appoints David Gill as Non-Executive Director - Sahm
[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3.63M indirect shares - Stock Titan
Telix (TLX) COO reports ordinary shares, ADRs and option-like awards - Stock Titan
Telix Pharmaceuticals (TLX) files 20-F/A to correct exhibit links - Stock Titan
Telix Pharmaceuticals (TLX) director reports 595,000 shares held via Forellan - Stock Titan
Telix (TLX) CEO details ADRs, options and large indirect stake - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3,719 Ordinary Shares - Stock Titan
Telix Pharmaceuticals Limited (TLX) Stock Price, News, Quote & History - Yahoo Finance
Telix (NASDAQ: TLX) resubmits FDA NDA for Pixclara brain cancer imaging agent - Stock Titan
Latest TLX NewsTelix to Showcase Urology Pipeline at Upcomi... - Stock Titan
Stock of the day: Telix Pharmaceuticals - ig.com
Telix Signals Upcoming Escrow Share Release - Colitco
How new prostate scans could change care: Telix hosts doctor Q&A - Stock Titan
Global prostate scan registry taps AI to predict survival - Stock Titan
Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz
Telix leaders to speak at Oppenheimer and TD Cowen, sessions streamed live - Stock Titan
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Telix submits European marketing application for brain cancer imaging agent By Investing.com - Investing.com India
Telix Pharmaceuticals stock rises after European regulatory submission By Investing.com - Investing.com India
Sea Limited Sponsored ADR (SE) Rises Higher Than Market: Key Facts - Yahoo Finance
New Telix brain scan aims to distinguish tumor growth from treatment effects - Stock Titan
Are Investors Undervaluing Yankuang Energy Group Company Limited Sponsored ADR (YZCAY) Right Now? - Yahoo Finance
Here's Why PDD Holdings Inc. Sponsored ADR (PDD) Fell More Than Broader Market - Yahoo Finance
Sea Limited Sponsored ADR (SE) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Is ANZ Group Holdings LimitedSponsored ADR (ANZGY) Outperforming Other Finance Stocks This Year? - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Advances While Market Declines: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Sea Limited Sponsored ADR (SE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RBC Capital upgrades Telix Pharmaceuticals stock rating to Outperform - Investing.com
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):